-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Kymera Therapeutics, Raises Price Target to $134

Benzinga·12/09/2025 15:28:18
語音播報
HC Wainwright & Co. analyst Andrew S. Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $84 to $134.